Lista de obras - Vikas Gupta - Dominio Público Uruguay

A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia

artículo científico publicado en 2016

A Prospective Study Comparing the Outcomes and Health-Related Quality of Life in Adult Patients with Myeloid Malignancies Undergoing Allogeneic Transplantation Using Myeloablative or Reduced-Intensity Conditioning ⬇️

artículo científico publicado el 12 de junio de 2011

A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.

artículo científico publicado en 2013

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

artículo científico publicado en 2012

A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies

artículo científico publicado en 2008

A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.

artículo científico publicado en 2015

A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis

artículo científico publicado en 2009

A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis

artículo científico publicado en 2014

A third course of anti-thymocyte globulin in aplastic anaemia is only beneficial in previous responders

artículo científico publicado en 2005

Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA.

artículo científico publicado en 2009

Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia ⬇️

artículo científico publicado el 25 de abril de 2011

Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia

artículo científico publicado en 2012

Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research

artículo científico publicado en 2009

Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy.

artículo científico publicado en 2011

Association of familial leukemia with HLA Cw3: is it real?

scientific article published on 01 February 2003

Cavernous sinus thrombosis presenting with diplopia in an allogeneic bone marrow transplant recipient

artículo científico publicado en 2004

Childhood obesity and outcomes after bone marrow transplantation for patients with severe aplastic anemia

artículo científico publicado en 2010

Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation.

artículo científico publicado en 2008

Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. ⬇️

artículo científico publicado en 2014

Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults

artículo científico publicado en 2006

Clinico-biological features and prognostic significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy

artículo científico publicado en 2004

Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission

artículo científico publicado en 2015

Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions.

artículo científico publicado en 2016

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies

scientific article published on 02 August 2013

Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR.

artículo científico publicado en 2013

Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.

artículo científico publicado en 2014

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.

artículo científico publicado en 2009

Evidence of graft-versus-Waldenstrom's macroglobulinaemia effect after allogeneic stem cell transplantation: a single centre experience

artículo científico publicado en 2007

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma

article

Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia

artículo científico publicado en 2004

Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia

scientific article published on 27 December 2011

Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies

artículo científico publicado en 2008

HLA-matched sibling transplantation for severe aplastic anemia: impact of HLA DR15 antigen status on engraftment, graft-versus-host disease, and overall survival.

artículo científico publicado en 2012

Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.

artículo científico publicado en 2010

Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation.

artículo científico publicado en 2010

Impaired T cell responsiveness to interleukin-6 in hematological patients with invasive aspergillosis

artículo científico publicado en 2015

Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan

scientific article published on 27 August 2007

Long-term outcomes in adult patients below the age of 55 years with acute lymphoblastic leukemia treated with chemotherapy or allogeneic BM transplant in first CR

artículo científico publicado en 2009

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

artículo científico publicado en 2014

Marrow transplantation for severe aplastic anemia with significant renal impairment

artículo científico publicado en 2007

Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability

scientific article published on 14 January 2019

Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score

scientific article published on 05 October 2014

Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response.

artículo científico publicado en 2014

Multiple myeloma and immune thrombocytopenia.

artículo científico publicado en 2000

Multiple single-nucleotide polymorphism-based risk model for clinical outcomes after allogeneic stem-cell transplantation, especially for acute graft-versus-host disease.

artículo científico publicado en 2012

Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.

artículo científico publicado en 2015

Natural killer-like T-cell leukaemia/lymphoma

artículo científico publicado en 2001

No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation

artículo científico publicado en 2012

Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation

artículo científico publicado en 2014

Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults

artículo científico publicado en 2010

Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia

artículo científico publicado en 2012

Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies

artículo científico publicado en 2014

Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation

artículo científico publicado en 2008

Outcomes of older patients (> or = 60 years) with acquired aplastic anaemia treated with immunosuppressive therapy.

artículo científico publicado en 2008

Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation

artículo científico publicado en 2015

Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2.

artículo científico publicado en 2015

Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation

scientific article published on 01 April 2009

Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission.

artículo científico publicado en 2005

Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen.

artículo científico publicado en 2013

Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy

scientific article published on 01 January 2008

Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age.

artículo científico publicado en 2015

Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia

artículo científico publicado en 2008

Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.

artículo científico publicado en 2013

Risk factors for acute GVHD and survival after hematopoietic cell transplantation ⬇️

artículo científico publicado el 18 de octubre de 2011

Risk model incorporating donor IL6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD

artículo científico publicado en 2015

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.

artículo científico publicado en 2011

The effect of smoking on allogeneic transplant outcomes.

artículo científico publicado en 2009

The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

artículo científico publicado en 2016

The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison.

artículo científico publicado en 2004

Tolerance to liver allograft after allogeneic hematopoietic cell transplantation for severe aplastic anemia from the same HLA-matched sibling donor

scientific article published on 14 November 2011

Treatment of Philadelphia chromosome‐positive acute lymphoblastic leukaemia with imatinib combined with a paediatric‐based protocol ⬇️

artículo científico publicado el 1 de junio de 2012

Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen

artículo científico publicado en 2009

Trisomy 4 as the sole cytogenetic abnormality in a patient with T-cell acute lymphoblastic leukemia.

artículo científico publicado en 2004

Lista de obras de Vikas Gupta

A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia

A Prospective Study Comparing the Outcomes and Health-Related Quality of Life in Adult Patients with Myeloid Malignancies Undergoing Allogeneic Transplantation Using Myeloablative or Reduced-Intensity Conditioning ⬇️

A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies

A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.

A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis

A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis

A third course of anti-thymocyte globulin in aplastic anaemia is only beneficial in previous responders

Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA.

Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia ⬇️

Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia

Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research

Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy.

Association of familial leukemia with HLA Cw3: is it real?

Cavernous sinus thrombosis presenting with diplopia in an allogeneic bone marrow transplant recipient

Childhood obesity and outcomes after bone marrow transplantation for patients with severe aplastic anemia

Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation.

Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. ⬇️

Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults

Clinico-biological features and prognostic significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy

Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission

Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions.

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies

Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR.

Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.

Evidence of graft-versus-Waldenstrom's macroglobulinaemia effect after allogeneic stem cell transplantation: a single centre experience

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma

Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia

Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia

Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies

HLA-matched sibling transplantation for severe aplastic anemia: impact of HLA DR15 antigen status on engraftment, graft-versus-host disease, and overall survival.

Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.

Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation.

Impaired T cell responsiveness to interleukin-6 in hematological patients with invasive aspergillosis

Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan

Long-term outcomes in adult patients below the age of 55 years with acute lymphoblastic leukemia treated with chemotherapy or allogeneic BM transplant in first CR

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

Marrow transplantation for severe aplastic anemia with significant renal impairment

Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability

Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score

Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response.

Multiple myeloma and immune thrombocytopenia.

Multiple single-nucleotide polymorphism-based risk model for clinical outcomes after allogeneic stem-cell transplantation, especially for acute graft-versus-host disease.

Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.

Natural killer-like T-cell leukaemia/lymphoma

No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation

Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation

Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults

Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia

Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies

Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation

Outcomes of older patients (> or = 60 years) with acquired aplastic anaemia treated with immunosuppressive therapy.

Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation

Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2.

Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation

Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission.

Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen.

Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy

Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age.

Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia

Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.

Risk factors for acute GVHD and survival after hematopoietic cell transplantation ⬇️

Risk model incorporating donor IL6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.

The effect of smoking on allogeneic transplant outcomes.

The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison.

Tolerance to liver allograft after allogeneic hematopoietic cell transplantation for severe aplastic anemia from the same HLA-matched sibling donor

Treatment of Philadelphia chromosome‐positive acute lymphoblastic leukaemia with imatinib combined with a paediatric‐based protocol ⬇️

Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen

Trisomy 4 as the sole cytogenetic abnormality in a patient with T-cell acute lymphoblastic leukemia.